Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.43 |
| ▸ | NPY1R | P25929 | 9/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.43 |
| ▸ | NPY2R | P49146 | 5/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | TMPRSS15 | P98073 | 2/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624778 | 0.93 | FOLH1 (0.48) | NPY4RNPY1RNPY5RNPY2RPRSS1 | |
| SCHEMBL30563225 | 0.90 | NOD1 (0.51) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL29473701 | 0.88 | NPY4R (0.42) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL16731685 | 0.88 | SIRT6 (0.43) | NPY4RNPY1RNPY5RNPY2RFOLH1 | |
| SCHEMBL18660499 | 0.86 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL29779797 | 0.86 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL30121059 | 0.86 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL30120978 | 0.86 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL29887603 | 0.86 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL30544289 | 0.86 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190352338-A1 | INHIBITORS FOR PROTEIN N-TERMINAL METHYLTRANSFERASE AND USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352338-A1 | INHIBITORS FOR PROTEIN N-TERMINAL METHYLTRANSFERASE AND USES THEREOF | GNMT, PRMT1, PRMT5 | NPY4R 4627/4885NPY1R 4573/4885NPY5R 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.